The Q3 results showed relatively minor deviations from our estimates and IFPM fell 2% y/y.
Company-compiled consensus and the share price had factored in a profit warning, but this did not pl...
Redeye saw a lower sales development than we expected, while Opex was lower than estimates.
Redeye provides its initial take on today’s announcement regarding the agreement with Wyld Networks ...
Taaleri announced today its new flagship fund, SolarWind III, in line with earlier communication.
Redeye comments on Vicore’s Q3 report, which came in as expected.
Elanders står stadigt och redovisar ett starkt resultat för Q3.
Q3 bjuder på rekordomsättning och svarta siffror på sista raden.
Redeye comments on Active Biotech's report for the third quarter and discusses several near-term mil...
Redeye retains its positive view on CombinedX despite a soft Q3 report.
Losses on bond portfolio behind net profit… … as indicated in net profit downgrade in October Core o...
Q3-rapporten Nettoomsättning för Q3 uppgick till 18,5 mkr (15,4) med ett rörelseresultat för kvartal...
Redeye endorses Saniona’s pre-clinical progress with drug candidate SAN903, that has compelling anti...
Redeye’s expectations were outdone by a wide margin.
Redeye comments on Stillfront’s announcement that it is evaluating closing down its subsidiary Ulka ...
Redeye saw sales substantially lower than our expectations for the quarter.
NOI increased 10% y-o-y, 1% vs ABGSCe Income from property management -7% vs.
Exel’s Q3 results came in soft relative to our estimates.
Redeye comments on yesterday’s news from Tessin, where the company announced a rights issue which, i...
Oceantech-bolaget Resqunit ska påbörja leverans av dess första order under mitten av november som fo...
